13 results
S-1
EX-10.4
TSHA
Taysha Gene Therapies Inc
2 Sep 20
IPO registration
5:02pm
of such oral communication.
Recalls. Company shall have the sole right to determine whether and how to implement a recall or other market withdrawal
10-K
2020 FY
EX-10.5
TSHA
Taysha Gene Therapies Inc
3 Mar 21
Annual report
9:00am
right to determine whether and how to implement a recall or other market withdrawal of the Licensed Product.
ARTICLE 5Financial Provisions
Initial Fee
10-Q
2020 Q3
TSHA
Taysha Gene Therapies Inc
12 Nov 20
Quarterly report
4:27pm
materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use … facility or us, including requesting a recall or requiring withdrawal of the drug from the market or suspension of manufacturing.
If we fail
8-K
EX-10.1
TSHA
Taysha Gene Therapies Inc
14 Aug 23
Entry into a Material Definitive Agreement
7:29am
of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension
10-K
4us2byo ptw9s36v9r
3 Mar 21
Annual report
9:00am
424B4
myggha5tdgix q316l
25 Sep 20
Prospectus supplement with pricing info
12:00am
S-1/A
89kiea8b
8 Sep 20
IPO registration (amended)
4:43pm
S-1
rzc256vktaq5x
2 Sep 20
IPO registration
5:02pm
DRS
hlo 8bfras
3 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next